453 related articles for article (PubMed ID: 23269097)
1. Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications.
Jonasson C; Hatlebakk JG; Lundell L; Kouri JP; Andersen M; Granath F
Eur J Gastroenterol Hepatol; 2013 May; 25(5):531-8. PubMed ID: 23269097
[TBL] [Abstract][Full Text] [Related]
2. Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding--a cohort study of the effects of proton pump inhibitor use patterns.
Hedberg J; Sundström J; Thuresson M; Aarskog P; Oldgren J; Bodegard J
J Intern Med; 2013 Oct; 274(4):371-80. PubMed ID: 23800296
[TBL] [Abstract][Full Text] [Related]
3. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage.
van Soest EM; Sturkenboom MC; Dieleman JP; Verhamme KM; Siersema PD; Kuipers EJ
Aliment Pharmacol Ther; 2007 Jul; 26(2):265-75. PubMed ID: 17593072
[TBL] [Abstract][Full Text] [Related]
4. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
5. The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study.
Ho CW; Tse YK; Wu B; Mulder CJ; Chan FK
Aliment Pharmacol Ther; 2013 Apr; 37(8):819-24. PubMed ID: 23432193
[TBL] [Abstract][Full Text] [Related]
6. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
[TBL] [Abstract][Full Text] [Related]
7. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
[TBL] [Abstract][Full Text] [Related]
8. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
Höer A; Gothe H; Schiffhorst G; Sterzel A; Grass U; Häussler B
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):854-8. PubMed ID: 17323403
[TBL] [Abstract][Full Text] [Related]
10. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
11. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
12. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE; Metge CJ; Leung S; Chateau DG
Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
[TBL] [Abstract][Full Text] [Related]
13. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases.
van Soest EM; Valkhoff VE; Mazzaglia G; Schade R; Molokhia M; Goldstein JL; Hernández-Díaz S; Trifirò G; Dieleman JP; Kuipers EJ; Sturkenboom MC
Gut; 2011 Dec; 60(12):1650-9. PubMed ID: 21636644
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
[TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
[TBL] [Abstract][Full Text] [Related]
17. Only full adherence to proton pump inhibitors protects against drug-induced upper gastrointestinal bleeding.
Ruiz B; Aguirre U; Estany-Gestal A; Rodella L; Ruiz P; Figueiras A; Carvajal A; Ibáñez L; Conforti A; de Pancorbo MM; Vidal X; Martin LH; Aguirre C
Eur J Clin Pharmacol; 2018 Nov; 74(11):1503-1511. PubMed ID: 30043109
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
19. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002.
Hermansson M; Ekedahl A; Ranstam J; Zilling T
BMC Gastroenterol; 2009 Apr; 9():25. PubMed ID: 19379513
[TBL] [Abstract][Full Text] [Related]
20. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
